ISSN 2394-5125
 

Research Article 


CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan.

Abstract
Haematological malignancies have been contributing significantly to the global burden of cancer
morbidities since ages. Moreover, relapsed and refractory cases of leukemias have proven to be real hardships
for the current medical and oncology practice. Chimeric Antigen Receptor-T (CAR-T) cell therapy has been a
breakthrough treatment for different haematological malignancies particularly Acute Lymphoblastic Leukemia
(ALL). Since its introduction in 2011, CAR-T cell therapy has improved significantly and is currently approved
for relapsed and refractory cases of ALL and Diffuses Large B-Cell Lymphoma (DLBCL). In this article, we
discuss about the evolution ladder of CAR-T cell therapy with respect to the three drugs namely
tisagenlecleucel, axicabtagene ciloleucel and lisocabtagene maraleucel, their limitations and future potential.

Key words: CAR-T cell therapy; Acute Lymphoblastic Leukemia; Diffuse Large B-Cell Lymphoma; Tisagenlecleucel; Axicabtagene ciloleucel; Lisocabtagene maraleucel


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Shubham Atal
Articles by Shah Newaz Ahmed
Articles by Malaya Nanda
Articles by Sadasivam Balakrishnan
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. JCR. 2020; 7(19): 6239-6243. doi:10.31838/jcr.07.19.722


Web Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. http://www.jcreview.com/?mno=133940 [Access: August 17, 2021]. doi:10.31838/jcr.07.19.722


AMA (American Medical Association) Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. JCR. 2020; 7(19): 6239-6243. doi:10.31838/jcr.07.19.722



Vancouver/ICMJE Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. JCR. (2020), [cited August 17, 2021]; 7(19): 6239-6243. doi:10.31838/jcr.07.19.722



Harvard Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan (2020) CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. JCR, 7 (19), 6239-6243. doi:10.31838/jcr.07.19.722



Turabian Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. 2020. CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. Journal of Critical Reviews, 7 (19), 6239-6243. doi:10.31838/jcr.07.19.722



Chicago Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. "CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES." Journal of Critical Reviews 7 (2020), 6239-6243. doi:10.31838/jcr.07.19.722



MLA (The Modern Language Association) Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan. "CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES." Journal of Critical Reviews 7.19 (2020), 6239-6243. Print. doi:10.31838/jcr.07.19.722



APA (American Psychological Association) Style

Shubham Atal, Shah Newaz Ahmed, Malaya Nanda, Sadasivam Balakrishnan (2020) CAR-T CELL THERAPY- TRANSFORMING TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. Journal of Critical Reviews, 7 (19), 6239-6243. doi:10.31838/jcr.07.19.722